| Filed On | Filing |
|---|---|
| 16 Nov 2026 |
Form 4: Wilson Troy Edward, Director
Bought 98,881 shares ($754K) · Bought 101,119 shares ($750K) |
| 16 Nov 2026 | 144 |
| 16 Nov 2026 | 144 |
| 16 Nov 2026 | 144 |
| 16 Nov 2026 | 144 |
| 16 Nov 2026 | 144 |
| 16 Nov 2026 | SCHEDULE 13G/A |
| 10 Nov 2026 | S-3ASR |
| 10 Nov 2026 | 10-Q |
| 10 Nov 2026 |
8-K: Results of Operations and Financial Condition
– KOMZIFTI®(ziftomenib) net product revenue grew 53% sequentially to $13.9 million; new patient starts increased 30% and total prescriptions grew 65% – |
| 27 Oct 2026 | SCHEDULE 13G/A |
| 29 Sep 2026 |
Form 4: Bair Teresa Brophy, Chief Legal Officer
Sold 8,442 shares ($88.6K) |
| 29 Sep 2026 |
Form 4: Ford Kathleen, Chief Operating Officer
Sold 6,906 shares ($72.5K) · Sold 3,668 shares ($39.4K) |
| 29 Sep 2026 |
Form 4: Leoni Mollie, Chief Medical Officer
Sold 12,448 shares ($131K) · Sold 28,802 shares ($310K) |
| 29 Sep 2026 |
Form 4: Doyle Thomas James, SVP, Finance & Accounting
Sold 4,607 shares ($48.4K) |
| 29 Sep 2026 |
Form 4: Powl Brian T., Chief Commercial Officer
Sold 17,020 shares ($179K) · Sold 15,430 shares ($166K) |
| 29 Sep 2026 | 144 |
| 29 Sep 2026 | 144 |
| 29 Sep 2026 | 144 |
| 28 Sep 2026 | 144 |
Loading...